DYN250117P15000
- 0.45
- -0.75-62.50%
Dyne Therapeutics Newsroom
Positive Outlook for Dyne Therapeutics as DYN-101 Shows Promising Clinical Results and Strategic Regulatory Advancements
Dyne Therapeutics: Positive Phase 1/2 Trial Results for DYNE-101 Lead to Buy Rating and Overweight Stock Recommendation
Small U.S. Stocks Close Lower; Dyne Therapeutics Posts Biggest Loss
12 Health Care Stocks Moving In Friday's Pre-Market Session
Dyne Therapeutics Is Maintained at Buy by Chardan Capital
Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?
Dyne Therapeutics Price Target Maintained With a $55.00/Share by HC Wainwright & Co.
RBC Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $45
H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
Dyne Therapeutics' Muscle Dystrophy Treatment Demonstrates DMPK Reduction, Splicing Correction; Shares Fall
Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact On Multiple Measures Of Myotonic Dystrophy Type 1; Company Plans To Initiate Registrational Expansion Cohort To Support Potential Submission For U.S. Accelerated Approval For...
Express News | Dyne Therapeutics Inc - Expects Completion of Enrollment for Registrational Expansion Cohort in Mid-2025
Express News | Dyne Therapeutics Inc - Dyne-101 Demonstrates Favorable Safety Profile in Achieve Trial
Express News | Dyne Therapeutics Inc - Plans U.S. Accelerated Approval Submission for Dyne-101 in H1 2026
Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Dyne Therapeutics Shares Jump Ahead of Clinical Data Review
Dyne Therapeutics Shares Are Trading Higher After the Company Announced It Will Release New Clinical Data From Its Phase 1/2 ACHIEVE Trial.
Dyne Therapeutics To Release New Clinical Data From Phase 1/2 ACHIEVE Trial On January 10, 2025; Investor Conference Call And Webcast Scheduled For 8:00 AM ET
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data From the ACHIEVE Trial Friday, January 10 at 8:00 A.m. ET
PepGen Stock Craters 35% on FDA Clinical Hold